Shino Kany
@shinokany.bsky.social
90 followers 99 following 34 posts
Cardiology and EP at UKE Hamburg, AI and Genetics at Broad Institute of MIT and Harvard.
Posts Media Videos Starter Packs
shinokany.bsky.social
Many thanks to my co-lead Sam Friedman, and co-authors Mostafa Al-Alusi, Shaan Khurshid, @joelramo.bsky.social, Daniel Pipilas, @jamespirruccello.com, Christopher Reeder, Anthony Philippakis, Jennifer Ho, Mahnaz Maddah, and the co-senior authors of this project, Patrick Ellinor, and Akl Fahed.
shinokany.bsky.social
In the BWH primary care cohort, individuals in the top quintile of ECG2CAD risk faced a 5–10× higher hazard of myocardial infarction or heart failure, and nearly 3× higher all-cause mortality over ~8 years.
shinokany.bsky.social
Performance remained consistent across age, sex, and race/ethnicity subgroups, and even on ECGs read as “normal” by cardiologists or in patients without classical risk factors.
shinokany.bsky.social
We observed a enhanced performance versus clinical risk scores such as PCE. This was particular seen in better average precision, which tells us how good a model flags high-risk individuals.
shinokany.bsky.social
Across three test sets, ECG2CAD achieved AUROCs of 0.78 (MGH), 0.75 (BWH) and 0.76 (UK Biobank), outperforming models based on aage and sex. When combined with age and sex, the minimal information a clinican would have, performance improved further.
shinokany.bsky.social
We developed ECG2CAD, a convolutional neural network trained on 764,670 12-lead ECGs from 137,036 patients at MGH, to predict prevalent CAD at the time of ECG. Validation was performed on independent cohorts from @MGH, Brigham & Women’s Hospital, and the UK Biobank.
shinokany.bsky.social
Coronary artery disease remains the leading cause of death globally, yet many individuals lack timely, noninvasive screening options. Deep learning applied to routine ECGs offers a scalable path to earlier detection, as shown in other diseases such as Afib or heart failure.
shinokany.bsky.social
Can a single ECG tell us who has coronary artery disease?

I’m excited to share the publication of our paper on using electrocardiogram-based artificial intelligence to predict prevalent coronary artery disease in @jaccjournals.bsky.social Advances.
shinokany.bsky.social
Im very honored to have been awarded with the Young Investigator Award "Arrhythmia" at the 91st annual meeting of the German Cardiac Society for our work on using clinical, genetic and AI risk for prediction of AF risk. Thanks for all co-authors and my mentors Shaan Khurshid and Patrick Ellinor.
Reposted by Shino Kany
jamespirruccello.com
Ever written an entire paper to fill out two empty cells in a table?

Along with @shinokany.bsky.social and colleagues, we did just that: proposing cutoffs for mild aortic stenosis using mean gradient, peak velocity, and aortic valve area (AVA). Free article:

authors.elsevier.com/a/1ks2B2d9GI...
A screenshot of a table showing current Mild AS definition, which lacks a distinction between normal and mild AS for AVA and mean gradient, and the proposed definition.
shinokany.bsky.social
Thanks, yeah they are wild. But thats also a function of directly measuring AV function instead of prediction. So was nice to see.
shinokany.bsky.social
I want to thank our collaborators from NEDA, Simon Stewart, David Playford, Geoff Strange and Yih-Kai Chan. The most enormous thanks go to my mentors @jamespirruccello.com and Patrick Ellinor. James is the brain behind all this and has guided me through this effort with great patience and support.
shinokany.bsky.social
I want to thank all our coauthors and collaborators: @joelramo.bsky.social , Cody Hou, Sean Jurgens, Victor Nauffal, @jonwcunningham.bsky.social, @emilyswlau.bsky.social, @atulbutte.bsky.social, Jeffrey Olgin, Sammy Elmariah, @markelindsay.bsky.social , and all participants at UK Biobank and NEDA.
shinokany.bsky.social
Our findings suggest that current definitions may miss a large group with prognostically significant aortic valve disease. Adopting our purely hemodynamic “mild ASproposed” thresholds could improve early identification and influence surveillance and prevention strategies.
shinokany.bsky.social
But what if this is only related to MRI and does not hold for the clinical standard diagnostic (Echo)? To answer this, we looked at the National Echo Database Australia (NEDA, N=365,870) where ASproposed criteria predicted increased all-cause mortality (HR 1.25) and CV mortality.
shinokany.bsky.social
Crucially, this definition identified almost all people at risk for AV replacement. The cumulative incidence of AV surgery by year 6 among those without AS (n = 46,988) was 0.032% compared with 1.8% with mild ASproposed , 17.4% with moderate AS (n = 271), and 56.2% in severe AS (n = 30).
shinokany.bsky.social
Applying these thresholds, 5.8% of participants were classified with mild ASproposed. They had a higher risk for AV procedures (HR 31.7), a risk of atrial fibrillation (HR 1.86), and heart failure (HR 2.37) compared with individuals without AS over ~4 years of follow-up.
shinokany.bsky.social
In a healthy subcohort (n=41,859), we derived reference ranges for AV function by age&sex. We defined “mild ASproposed” (outside the 95th percentile >any age group) as any 1 of these criteria: peak velocity >1.65 m/s, mean gradient >4.8 mmHg, or AVA <2.1 cm² (men) / <1.7 cm² (women).
shinokany.bsky.social
However, the UK Biobank MRIs don't come with clinical reports. So, we developed a deep learning model to segment the blood pool above the asc.aorta which allowed us to quantify aortic valve area, peak velocity, and mean gradient from velocity-encoded MRI data in 62,902 UK Biobank participants.
shinokany.bsky.social
So, we wanted to see what “normal” aortic valve (AV) function is and what clinical consequences would be associated with abnormal AV function. However, we would need a population-based cohort with imaging without clinical indication. Enter the UK Biobank, a prospective cohort study from the UK.
shinokany.bsky.social
Aortic stenosis (AS) is the most common valve lesion. There is no medical treatment and major trials focus on moderate/severe AS. But what if we should intervene earlier for meds to work? Issue is “mild AS” is only defined for peak velocity and w/ varying definitions (Vmax 2-2.9m/s or 2.6-2.9m/s).
shinokany.bsky.social
Happy to share our study “New Threshold for Defining Mild Aortic Stenosis Derived From Velocity-Encoded MRI in 60,000 Individuals” in which we identify a new threshold for Mild AS and the consequences of early aortic valve dysfunction. @jamespirruccello.com

authors.elsevier.com/a/1ks2B2d9GI...
shinokany.bsky.social
Thank you, Ezim!
shinokany.bsky.social
I extend my heartfelt gratitude to my mentors Patrick Ellinor and Shaan Khurshid whose unwavering patience and guidance continue to inspire and support me every day. And of course all institutions: UKE Hamburg, @broadinstitute.org and Mass General.
shinokany.bsky.social
This work was possible thanks to prior work and amazing co-authors Mostafa Al-Alusi, @joelramo.bsky.social, @jamespirruccello.com, @ajufoezim.bsky.social , Tim Churchill, Steven Lubitz, Mahnaz Maddah, @jsawallagusehmd.bsky.social and all @ukbiobank.bsky.social participants.